Skip to main content

Navigation group

Volumes

110 Publications

Volume 2 - 2023

Original Research

Published on 23 Oct 2023

Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason

  • Giammarco Mocci
  • Arianna Cingolani
  • Giorgia Orrù
  • Carla Felice
  • Francesca Maria Onidi
  • Gianmarco Lombardi
  • Davide Checchin
  • Raffaele Colucci
  • Laurino Grossi
  • Antonio Ferronato
Adalimumab biosimilar ABP 501 is equally effective and safe in long-term management of inflammatory bowel diseases patients when used as first biologic treatment or as replace of the ADA originator for a non-medical reason
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1218228
  • 487 views
  • 1 citation